A New Way to Think About this stock: Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

On 08 Jan 2020, Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) spotted trading -58.23% off 52-week high price. On the other end, the stock has been noted 20.69% away from the low price over the last 52-weeks. The stock changed -2.78% to recent value of $1.75. The stock transacted 142027 shares during most recent day however it has an average volume of 181.41K shares. The company has 28.66M of outstanding shares and 23.04M shares were floated in the market.

Idera Pharmaceuticals, Inc (IDRA) recently stated its operational and financial results for the third quarter ended September 30, 2019.

Financial Results
Third Quarter Results
Net loss applicable to ordinary stockholders for the three months ended September 30, 2019 was $11.1M, or $0.39 per basic and diluted share, contrast to net loss applicable to ordinary stockholders of $11.6M, or $0.43 per basic and diluted share, for the same period in 2018. Research and development expenses for the three months ended September 30, 2019 totaled $8.4M contrast to $8.9M for the same period in 2018. General and administrative expense for the three months ended September 30, 2019 totaled $3.0M contrast to $4.0M for the same period in 2018. Merger-related costs, net for the three months ended September 30, 2018 amounted to a net credit of $3.8M and was comprised of a $6.0M fixed expense reimbursement received in connection with the termination of a merger contract in July 2018, partially offset by $2.2M of expenses incurred in connection with transactions contemplated by such merger contract. No such costs were incurred for the same period in 2019. Restructuring costs for the three months ended September 30, 2019 were less than $0.1M contrast to $3.0M for the same period in 2018 and related to our decision in July 2018 to wind-down our discovery operations.

As of September 30, 2019, our cash, cash equivalents and short-term investments totaled $41.6M contrast to $71.4M as of December 31, 2018.  We presently anticipate that, based on our current operating plan, our existing cash, cash equivalents and investments on hand as of September 30, 2019, will fund our operations into the third quarter of 2020.

The price moved ahead of 1.61% from the mean of 20 days, -12.45% from mean of 50 days SMA and performed -30.21% from mean of 200 days price. Company’s performance for the week was -3.85%, -3.31% for month and YTD performance remained -3.85%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *